| Autor: |
Kumaraswami, Konda, Katkam, Shiva Krishna, Aggarwal, Amita, Sharma, Aman, Manthri, Ramesh, Kutala, Vijay Kumar, Rajasekhar, Liza |
| Zdroj: |
Pharmacogenomics; October 2017, Vol. 18 Issue: 15 p1401-1411, 11p |
| Abstrakt: |
Aim:To investigate the impact of genetic variants in CYP2C9, CYP2C19, CYP3A4, GSTT1, GSTM1and GSTP1on the efficacy of cyclophosphamide (CYC) therapy in patients with lupus nephritis. Materials & methods:Lupus nephritis patients (n 220) treated with CYC were included in the study. Results:Logistic regression analysis identified CYP2C192as an independent predictor of CYC therapeutic failure (odds ratio [OR]: 2.69; p 0.0043). Bivariate and trivariate analysis showed the subjects harboring CYP2C192and GSTP1(OR: 3.25; p 0.03), and CYP2C192, GSTP1and CYP3A53have synergistic influence on CYC failure (OR: 8.2; p < 0.0001). Significant decrease in AUC0-t, Cmaxand t½of 4-OH-CYC in patients carrying CYP3A53(p < 0.02). Conclusion:Patients with CYP2C192were at increased risk and CYP2C192, CYP3A53and GSTP1have synergistic influence on CYC failure. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
